As of 2025-09-18, the EV/EBITDA ratio of Anika Therapeutics Inc (ANIK) is -24.00. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Anika's latest enterprise value is 71.71 mil USD. Anika's TTM EBITDA according to its financial statements is -2.99 mil USD. Dividing these 2 quantities gives us the above Anika EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 14.3x | 11.0x |
| Forward P/E multiples | 15.6x - 21.5x | 19.4x |
| Fair Price | 2.21 - 8.78 | 4.85 |
| Upside | -74.5% - 1.4% | -44.0% |
| Date | EV/EBITDA |
| 2025-09-17 | -24.00 |
| 2025-09-16 | -23.95 |
| 2025-09-15 | -23.95 |
| 2025-09-12 | -24.05 |
| 2025-09-11 | -23.85 |
| 2025-09-10 | -22.74 |
| 2025-09-09 | -24.34 |
| 2025-09-08 | -25.35 |
| 2025-09-05 | -25.35 |
| 2025-09-04 | -26.07 |
| 2025-09-03 | -25.69 |
| 2025-09-02 | -26.36 |
| 2025-08-29 | -27.47 |
| 2025-08-28 | -26.75 |
| 2025-08-27 | -26.51 |
| 2025-08-26 | -27.23 |
| 2025-08-25 | -26.27 |
| 2025-08-22 | -28.78 |
| 2025-08-21 | -25.88 |
| 2025-08-20 | -22.60 |
| 2025-08-19 | -23.66 |
| 2025-08-18 | -24.14 |
| 2025-08-15 | -24.82 |
| 2025-08-14 | -23.90 |
| 2025-08-13 | -26.03 |
| 2025-08-12 | -24.29 |
| 2025-08-11 | -21.83 |
| 2025-08-08 | -21.35 |
| 2025-08-07 | -21.88 |
| 2025-08-06 | -22.02 |
| 2025-08-05 | -22.50 |
| 2025-08-04 | -24.53 |
| 2025-08-01 | -23.90 |
| 2025-07-31 | -22.04 |
| 2025-07-30 | -21.30 |
| 2025-07-29 | -36.06 |
| 2025-07-28 | -36.88 |
| 2025-07-25 | -37.71 |
| 2025-07-24 | -36.79 |
| 2025-07-23 | -37.71 |
| 2025-07-22 | -35.29 |
| 2025-07-21 | -33.80 |
| 2025-07-18 | -32.88 |
| 2025-07-17 | -36.45 |
| 2025-07-16 | -36.21 |
| 2025-07-15 | -35.29 |
| 2025-07-14 | -37.85 |
| 2025-07-11 | -36.60 |
| 2025-07-10 | -39.06 |
| 2025-07-09 | -35.97 |